ES2523024T3 - Tratamiento de glucogenosis de tipo II - Google Patents

Tratamiento de glucogenosis de tipo II Download PDF

Info

Publication number
ES2523024T3
ES2523024T3 ES07001091.3T ES07001091T ES2523024T3 ES 2523024 T3 ES2523024 T3 ES 2523024T3 ES 07001091 T ES07001091 T ES 07001091T ES 2523024 T3 ES2523024 T3 ES 2523024T3
Authority
ES
Spain
Prior art keywords
treatment
type
glycogenosis
months
storage disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES07001091.3T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2523024(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duke University filed Critical Duke University
Application granted granted Critical
Publication of ES2523024T3 publication Critical patent/ES2523024T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

α-Glucosidasa ácida (GAA) humana recombinante producida en un cultivo celular de ovario de hámster chino para uso en un método de tratamiento de la glucogenosis de tipo II en un ser humano, o para uso en un método de tratamiento de la cardiomiopatía asociada con la glucogenosis de tipo II en un ser humano, donde el ser humano es CRIM (material immunoreactivo de reacción cruzada)-positivo para la α-glucosidasa ácida endógena.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
E07001091
03-11-2014
Tabla 2. Datos clínicos de referencia en 3 pacientes con enfermedad de Pompe infantil
Número depaciente/sexo
Origen étnico Edad inicioGAArh Estado cardiaco Función pulmonar Desarrollomotor(puntuaciónAIMS) Actividad GAAen fibroblastosde la piel (% denormal) EstadoCRIM* Edadactual
Paciente1/masculino
Caucásico 4 meses Cardiomiopatíasevera; estadopost ataquecardiaco Límite normal,compresiónbronquio principalizquierdo por unamarcadacardiomegalia,desaturación O2 <<5º% 0,84% Negativo 29 meses
Paciente2/masculino
Afro-Americano 3 meses Cardiomiopatíamoderada Desaturación O2durante el llanto <5º% 0,57% Negativo 25 meses
Paciente3/masculino
Caucásico 2½ meses Cardiomiopatíalímite normal <<5º% 0,69% Positivo 23 meses
*CRIM = material inmunoreactivo de reacción cruzada
7
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES07001091.3T 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II Expired - Lifetime ES2523024T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
US219237P 2000-07-18

Publications (1)

Publication Number Publication Date
ES2523024T3 true ES2523024T3 (es) 2014-11-20

Family

ID=22818451

Family Applications (5)

Application Number Title Priority Date Filing Date
ES18194771T Expired - Lifetime ES2799882T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES01951000T Expired - Lifetime ES2277931T3 (es) 2000-07-18 2001-07-10 Tratamiento de la glucogenesis de tipo ii.
ES16178390T Expired - Lifetime ES2700865T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES14167882.1T Expired - Lifetime ES2599401T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES07001091.3T Expired - Lifetime ES2523024T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ES18194771T Expired - Lifetime ES2799882T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES01951000T Expired - Lifetime ES2277931T3 (es) 2000-07-18 2001-07-10 Tratamiento de la glucogenesis de tipo ii.
ES16178390T Expired - Lifetime ES2700865T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II
ES14167882.1T Expired - Lifetime ES2599401T3 (es) 2000-07-18 2001-07-10 Tratamiento de glucogenosis de tipo II

Country Status (18)

Country Link
US (10) US7056712B2 (es)
EP (4) EP3449934B1 (es)
JP (10) JP5113312B2 (es)
AT (1) ATE355075T1 (es)
AU (3) AU2001271941B2 (es)
BR (1) BR0113006A (es)
CA (1) CA2416492C (es)
CY (2) CY1120977T1 (es)
DE (1) DE60126947T2 (es)
DK (5) DK1782825T3 (es)
ES (5) ES2799882T3 (es)
HK (3) HK1054690A1 (es)
LT (3) LT3108895T (es)
MX (1) MXPA03000474A (es)
PT (5) PT3108895T (es)
SI (3) SI3449934T1 (es)
TW (1) TWI280882B (es)
WO (1) WO2002005841A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2799882T3 (es) * 2000-07-18 2020-12-22 Univ Duke Tratamiento de glucogenosis de tipo II
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2445577C (en) * 2001-04-30 2012-07-03 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
WO2005078077A2 (en) * 2004-02-10 2005-08-25 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP1773401B1 (en) * 2004-06-21 2013-01-02 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
DK2279210T3 (en) 2008-05-07 2017-07-24 Biomarin Pharm Inc Lysosomal targeting peptides and uses thereof
WO2010005565A2 (en) 2008-07-08 2010-01-14 Duke University Method of treating glycogen storage disease
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
CN115120745A (zh) * 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经***转移
FI3201320T3 (fi) 2014-09-30 2024-01-08 Amicus Therapeutics Inc Erittäin tehokas hapan alfa-glukosidaasi parannetuilla hiilihydraateilla
JP6821192B2 (ja) * 2015-05-07 2021-01-27 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
MA44747A (fr) * 2015-08-31 2019-03-06 Univ Duke Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR20220145918A (ko) 2016-03-30 2022-10-31 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
CA3019128A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
IL305449A (en) 2016-04-15 2023-10-01 Univ Pennsylvania Gene therapy for the treatment of type II mucositis
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
IL139616A0 (en) 1998-05-13 2002-02-10 Harbor Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof
KR20010101131A (ko) * 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
ES2799882T3 (es) * 2000-07-18 2020-12-22 Univ Duke Tratamiento de glucogenosis de tipo II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2005078077A2 (en) * 2004-02-10 2005-08-25 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
SI3108895T1 (sl) 2019-01-31
JP2020019822A (ja) 2020-02-06
EP2767291B1 (en) 2016-09-14
BR0113006A (pt) 2004-10-19
US9907839B2 (en) 2018-03-06
JP5792774B2 (ja) 2015-10-14
HK1103363A1 (en) 2007-12-21
DK1782825T3 (da) 2014-11-03
MXPA03000474A (es) 2003-10-06
US20020110551A1 (en) 2002-08-15
ATE355075T1 (de) 2006-03-15
DK1301201T3 (da) 2007-04-02
LT2767291T (lt) 2016-11-25
EP1301201A1 (en) 2003-04-16
PT3449934T (pt) 2020-06-25
US20150004152A1 (en) 2015-01-01
US20050123531A1 (en) 2005-06-09
US8900552B2 (en) 2014-12-02
JP2014185187A (ja) 2014-10-02
JP2016056206A (ja) 2016-04-21
EP3108895B1 (en) 2018-09-19
DK3449934T3 (da) 2020-06-29
PT1782825E (pt) 2014-11-04
CY1123084T1 (el) 2021-10-29
WO2002005841A1 (en) 2002-01-24
JP2012006953A (ja) 2012-01-12
ES2700865T3 (es) 2019-02-19
US20210169996A1 (en) 2021-06-10
US20130195834A1 (en) 2013-08-01
JP2008081507A (ja) 2008-04-10
EP3449934A1 (en) 2019-03-06
DK2767291T3 (en) 2016-12-05
JP2013231081A (ja) 2013-11-14
ES2277931T3 (es) 2007-08-01
JP6163216B2 (ja) 2017-07-12
US20080175833A1 (en) 2008-07-24
EP2767291A2 (en) 2014-08-20
EP3108895A1 (en) 2016-12-28
PT3108895T (pt) 2018-12-18
US20120058132A1 (en) 2012-03-08
DE60126947D1 (de) 2007-04-12
US20180185457A1 (en) 2018-07-05
US9370556B2 (en) 2016-06-21
ES2799882T3 (es) 2020-12-22
EP1301201B1 (en) 2007-02-28
DK3108895T3 (en) 2018-11-26
CA2416492C (en) 2008-04-29
ES2599401T3 (es) 2017-02-01
US7056712B2 (en) 2006-06-06
US20100254966A1 (en) 2010-10-07
SI2767291T1 (sl) 2016-11-30
AU2001271941B2 (en) 2007-03-01
SI3449934T1 (sl) 2020-09-30
AU2010200487A1 (en) 2010-03-04
US20160184410A1 (en) 2016-06-30
JP5113312B2 (ja) 2013-01-09
AU7194101A (en) 2002-01-30
EP3449934B1 (en) 2020-05-20
DE60126947T2 (de) 2007-10-31
CY1120977T1 (el) 2019-12-11
HK1054690A1 (en) 2003-12-12
CA2416492A1 (en) 2002-01-24
JP2004503598A (ja) 2004-02-05
PT2767291T (pt) 2016-10-25
JP2018002749A (ja) 2018-01-11
LT3108895T (lt) 2018-11-26
HK1197656A1 (zh) 2015-02-06
JP2017137357A (ja) 2017-08-10
LT3449934T (lt) 2020-08-10
EP2767291A3 (en) 2014-10-08
US10792341B2 (en) 2020-10-06
PT1301201E (pt) 2007-03-30
JP2018199721A (ja) 2018-12-20
TWI280882B (en) 2007-05-11

Similar Documents

Publication Publication Date Title
ES2523024T3 (es) Tratamiento de glucogenosis de tipo II
ANDERSON et al. Myocardial toxicity from carbon monoxide poisoning
Marks et al. A new form of long QT syndrome associated with syndactyly
Alhady et al. Total paralysis regime in severe tetanus
Dhurandhar et al. Bretylium tosylate in the management of refractory ventricular fibrillation
Lewin et al. Non-invasive evaluation of electrical cardiac injury.
Brockmann et al. Fatal poisoning with sodium fluoroacetate: report of a case
Ellenberg et al. Pseudo ariboflavinosis
Nonomura et al. A case of pharyngolaryngeal stenosis in Behçet's disease
Wayne et al. Exercise-Induced ST Segment Alternane
Bourke et al. Diabetes mellitus in patients with benign prostatic hyperplasia
Gavaghan et al. Dilated cardiomyopathy in an American Cocker Spaniel with taurine deficiency
CN1350455A (zh) 维生素联合应用治疗搔痒症和涉及搔痒和/或炎症的非感染性疾病
Wanninayake et al. Hypernatraemia after treatment of hydatid.
Moynahan XTE syndrome (xeroderma, talipes and enamel defect): a new heredo-familial syndrome. Two cases. Homozygous inheritance of a dominant gene
CARTER et al. Studies of the blood gases in a case of paroxysmal tachycardia
Rachmilewitz et al. The presence of electrocardiographic changes in nicotinic acid deficiency and their elimination by nicotinic acid
Thomas et al. Electrocardiographic changes in catastrophic abdominal illness mimicking acute myocardial infarction
Ellman Sudden death
CN215689270U (zh) 一种心内科摇摆式侧卧床
du Vivier et al. Xanthoma disseminatum
Hodkinson et al. The Romano-Ward syndrome--1964-2014: 50 years of progress.
Rachmilewitz et al. Electrocardiographic changes and the effect of niacin therapy in pellagra
Nickel et al. ALTERED PROGNOSIS WITH CARDIAC MASSAGE: CARDIAC RESUSCITATION IN ACUTE MYOCARDIAL INFARCTION-REPORT OF TWO SUCCESSFULLY TREATED CASES
TerzIoglu et al. Surgical correction of microstomia in a patient with scleroderma